NCT03480594

Brief Summary

The investigators plan to evaluate sensitivity and specificity of HP 13C-pyruvate as an imaging agent for detection of altered PDH flux in fatty liver.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 21, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 29, 2018

Completed
6 months until next milestone

Study Start

First participant enrolled

October 1, 2018

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 13, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 13, 2023

Completed
Last Updated

February 19, 2025

Status Verified

February 1, 2025

Enrollment Period

5 years

First QC Date

March 21, 2018

Last Update Submit

February 17, 2025

Conditions

Fatty Liver

Outcome Measures

Primary Outcomes (1)

  • Bicarbonate:lactate ratio

    1\. The ratio of hyperpolarized \[13C\]bicarbonate relative to hyperpolarized \[1-13C\]lactate. This measurement will be monitored from the subject's liver over a \~4 minute period in the MRI system.

    One visit of 6 hours; two injections of HP pyruvate with MRI over 3 hours

Secondary Outcomes (1)

  • Labeled glycerol fraction

    One visit of 6 hours; ingestion of Oral Glycerol with blood draws over 3 hours

Study Arms (2)

Fatty Liver Patients

Hyperpolarized \[13C\] Pyruvate Injection in Fatty Liver patients

Drug: MRI Tracer

Healthy Control Subjects

Hyperpolarized \[13C\] Pyruvate Injection in Healthy Control Subjects

Drug: MRI Tracer

Interventions

MRI TracerDRUG

Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.

Fatty Liver PatientsHealthy Control Subjects

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The plan is to study fatty liver patients and healthy subjects

You may qualify if:

  • Ages 18 to 99 years.

You may not qualify if:

  • Either fatty liver diagnosis (defined as \>5.6% fat content in the liver) or healthy control
  • While all races and ethnicities will be included, subjects must be able to read and speak the English language. Once the protocol is established, Spanish-speaking participants will be included.
  • Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Fatty Liver Subjects
  • Subjects with major mental health conditions such as schizophrenia and bipolar disorder that would limit compliance with study requirements will not participate. In general, subjects with any form of medical instability such as seizure disorders, significant COPD, significant asthma, left ventricular dysfunction will not participate.
  • Medications for control of hypercholesterolemia, hypertriglyceridemia or hyperglycemia.
  • Healthy Control Subjects
  • Liver disease or other chronic illness
  • Diagnosis of type I or type II diabetes
  • A potential subject with any major medical, surgical or psychiatric condition will not participate. These conditions include but are not limited to thyroid disease, chronic metabolic illness, known vascular disease, current cancer diagnosis and/or treatment.
  • Subjects with major mental health conditions such as schizophrenia and bipolar disorder that would limit compliance with study requirements will not participate. In general, subjects with any form of medical instability such as seizure disorders, significant COPD, significant asthma, left ventricular dysfunction will not participate.
  • Medications for control of hypercholesterolemia, hypertriglyceridemia or hyperglycemia.
  • All Subjects
  • No prior hepato-biliary surgery.
  • Donated blood within the prior 4 weeks.
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Advanced Imaging Research Center

Dallas, Texas, 75390-8568, United States

Location

Related Publications (21)

  • Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63. doi: 10.1073/pnas.1733835100. Epub 2003 Aug 20.

    PMID: 12930897BACKGROUND

  • Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Sci Transl Med. 2013 Aug 14;5(198):198ra108. doi: 10.1126/scitranslmed.3006070.

    PMID: 23946197BACKGROUND

  • Cunningham CH, Lau JY, Chen AP, Geraghty BJ, Perks WJ, Roifman I, Wright GA, Connelly KA. Hyperpolarized 13C Metabolic MRI of the Human Heart: Initial Experience. Circ Res. 2016 Nov 11;119(11):1177-1182. doi: 10.1161/CIRCRESAHA.116.309769. Epub 2016 Sep 15.

    PMID: 27635086BACKGROUND

  • Neeland IJ, Hughes C, Ayers CR, Malloy CR, Jin ES. Effects of visceral adiposity on glycerol pathways in gluconeogenesis. Metabolism. 2017 Feb;67:80-89. doi: 10.1016/j.metabol.2016.11.008. Epub 2016 Nov 27.

    PMID: 28081781BACKGROUND

  • Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 May;37(5):1202-19. doi: 10.1053/jhep.2003.50193.

    PMID: 12717402BACKGROUND

  • Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, He T, Nair LA, Livingston KA, Fu X, Merritt ME, Sherry AD, Malloy CR, Shelton JM, Lambert J, Parks EJ, Corbin I, Magnuson MA, Browning JD, Burgess SC. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest. 2015 Dec;125(12):4447-62. doi: 10.1172/JCI82204. Epub 2015 Nov 16.

    PMID: 26571396BACKGROUND

  • Satapati S, Sunny NE, Kucejova B, Fu X, He TT, Mendez-Lucas A, Shelton JM, Perales JC, Browning JD, Burgess SC. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res. 2012 Jun;53(6):1080-92. doi: 10.1194/jlr.M023382. Epub 2012 Apr 9.

    PMID: 22493093BACKGROUND

  • Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011 Dec 7;14(6):804-10. doi: 10.1016/j.cmet.2011.11.004.

    PMID: 22152305BACKGROUND

  • Jones JG. Hepatic glucose and lipid metabolism. Diabetologia. 2016 Jun;59(6):1098-103. doi: 10.1007/s00125-016-3940-5. Epub 2016 Apr 5.

    PMID: 27048250BACKGROUND

  • Jin ES, Moreno KX, Wang JX, Fidelino L, Merritt ME, Sherry AD, Malloy CR. Metabolism of hyperpolarized [1-(13)C]pyruvate through alternate pathways in rat liver. NMR Biomed. 2016 Apr;29(4):466-74. doi: 10.1002/nbm.3479. Epub 2016 Feb 2.

    PMID: 26836042BACKGROUND

  • Jin ES, Sherry AD, Malloy CR. An Oral Load of [13C3]Glycerol and Blood NMR Analysis Detect Fatty Acid Esterification, Pentose Phosphate Pathway, and Glycerol Metabolism through the Tricarboxylic Acid Cycle in Human Liver. J Biol Chem. 2016 Sep 2;291(36):19031-41. doi: 10.1074/jbc.M116.742262. Epub 2016 Jul 18.

    PMID: 27432878BACKGROUND

  • Jin ES, Sherry AD, Malloy CR. Interaction between the pentose phosphate pathway and gluconeogenesis from glycerol in the liver. J Biol Chem. 2014 Nov 21;289(47):32593-603. doi: 10.1074/jbc.M114.577692. Epub 2014 Oct 6.

    PMID: 25288790BACKGROUND

  • Lee P, Leong W, Tan T, Lim M, Han W, Radda GK. In vivo hyperpolarized carbon-13 magnetic resonance spectroscopy reveals increased pyruvate carboxylase flux in an insulin-resistant mouse model. Hepatology. 2013 Feb;57(2):515-24. doi: 10.1002/hep.26028. Epub 2013 Jan 10.

    PMID: 22911492BACKGROUND

  • Moreno KX, Moore CL, Burgess SC, Sherry AD, Malloy CR, Merritt ME. Production of hyperpolarized 13CO2 from [1-13C]pyruvate in perfused liver does reflect total anaplerosis but is not a reliable biomarker of glucose production. Metabolomics. 2015 Oct;11(5):1144-1156. doi: 10.1007/s11306-014-0768-1. Epub 2015 Jan 9.

    PMID: 26543443BACKGROUND

  • Merritt ME, Harrison C, Sherry AD, Malloy CR, Burgess SC. Flux through hepatic pyruvate carboxylase and phosphoenolpyruvate carboxykinase detected by hyperpolarized 13C magnetic resonance. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19084-9. doi: 10.1073/pnas.1111247108. Epub 2011 Nov 7.

    PMID: 22065779BACKGROUND

  • Moreno KX, Satapati S, DeBerardinis RJ, Burgess SC, Malloy CR, Merritt ME. Real-time detection of hepatic gluconeogenic and glycogenolytic states using hyperpolarized [2-13C]dihydroxyacetone. J Biol Chem. 2014 Dec 26;289(52):35859-67. doi: 10.1074/jbc.M114.613265. Epub 2014 Oct 28.

    PMID: 25352600BACKGROUND

  • Moreno KX, Harrison CE, Merritt ME, Kovacs Z, Malloy CR, Sherry AD. Hyperpolarized delta-[1-13 C]gluconolactone as a probe of the pentose phosphate pathway. NMR Biomed. 2017 Jun;30(6):10.1002/nbm.3713. doi: 10.1002/nbm.3713. Epub 2017 Mar 8.

    PMID: 28272754BACKGROUND

  • Jin ES, Szuszkiewicz-Garcia M, Browning JD, Baxter JD, Abate N, Malloy CR. Influence of liver triglycerides on suppression of glucose production by insulin in men. J Clin Endocrinol Metab. 2015 Jan;100(1):235-43. doi: 10.1210/jc.2014-2404.

    PMID: 25250633BACKGROUND

  • Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, Jiang L, Ko B, Skelton R, Loudat L, Wodzak M, Klimko C, McMillan E, Butt Y, Ni M, Oliver D, Torrealba J, Malloy CR, Kernstine K, Lenkinski RE, DeBerardinis RJ. Metabolic Heterogeneity in Human Lung Tumors. Cell. 2016 Feb 11;164(4):681-94. doi: 10.1016/j.cell.2015.12.034. Epub 2016 Feb 4.

    PMID: 26853473BACKGROUND

  • Pichumani K, Mashimo T, Vemireddy V, Kovacs Z, Ratnakar J, Mickey B, Malloy CR, DeBerardinis RJ, Bachoo RM, Maher EA. Hepatic gluconeogenesis influences (13)C enrichment in lactate in human brain tumors during metabolism of [1,2-(13)C]acetate. Neurochem Int. 2016 Jul;97:133-6. doi: 10.1016/j.neuint.2016.03.015. Epub 2016 Mar 26.

    PMID: 27020407BACKGROUND

  • Cheshkov S, Dimitrov IE, Jakkamsetti V, Good L, Kelly D, Rajasekaran K, DeBerardinis RJ, Pascual JM, Sherry AD, Malloy CR. Oxidation of [U-13 C]glucose in the human brain at 7T under steady state conditions. Magn Reson Med. 2017 Dec;78(6):2065-2071. doi: 10.1002/mrm.26603. Epub 2017 Jan 23.

    PMID: 28112825BACKGROUND

MeSH Terms

Conditions

Fatty Liver

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 21, 2018

First Posted

March 29, 2018

Study Start

October 1, 2018

Primary Completion

October 13, 2023

Study Completion

October 13, 2023

Last Updated

February 19, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations

US(1)